Background {#Sec1}
==========

Sepsis, especially severe sepsis and septic shock are associated with a high rate of death and complications. It has been reported that the annual incidence of severe sepsis and septic shock in the United States is up to 300 cases per 100,000 people \[[@CR1]--[@CR3]\]. Despite the advances in the therapy of severe sepsis and septic shock, the mortality of these patients remains high, ranging from 20 % to 50 % \[[@CR4]--[@CR6]\]. In 2001, a randomized, non-blinded, controlled trial conducted by Rivers reported that patients with severe sepsis and septic shock presenting to the emergency department had a lower mortality rate, if they received a specific 6 h resuscitation bundle of early-goal directed therapy (EGDT), and the absolute risk reduction was 16 % \[[@CR7]\]. Therefore, EGDT was recommended by the 2004, 2008 and 2012 surviving sepsis campaigning (SSC) guidelines \[[@CR8]--[@CR10]\]. Meanwhile, several observational studies also found the survival benefit of standard EGDT or modified EGDT in comparison to usual care \[[@CR11]--[@CR29]\]. However, the effect of EGDT was questioned in three multicenter randomized controlled trials, namely ProCESS, ARISE and ProMISe. The authors reported that EGDT did not reduce the mortality rate of patients with severe sepsis and septic shock as compared with usual care \[[@CR6], [@CR30], [@CR31]\]. In a meta-analysis, Gu reported that EGDT significantly reduces the overall mortality of patients with sepsis. However, several limitations of this study should be noted: firstly, the newest studies of ARISE and ProMISe study were not included; secondly, the included studies in this meta-analysis were published between 1992 and 2014, during which time the standard care of sepsis as well as the definition of sepsis had changed a lot; Thirdly, this meta-analysis ignored the fact that the pooled results of China-centric studies were significantly different from the pooled results of America and Australia-centric studies; Finally, several studies included in this meta-analysis did not meet the inclusion criteria (one was not a RCT but a before-and-after study; one included patients with systemic inflammatory response syndrome not sepsis and one evaluated modified EGDT not standard EGDT) \[[@CR32]\]. The objective of our study was to systematically evaluate the effect of EGDT on patients with severe sepsis and septic shock.

Methods {#Sec2}
=======

We had registered the present meta-analysis protocol in PROSPERO (<http://www.crd.york.ac.uk/PROSPERO/>; CRD42015017667). Our meta-analysis was conducted and reported based on The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@CR33]\].

Data sources {#Sec3}
------------

The following databases: PubMed, EMBASE, the Cochrane library, and a Chinese database (SinoMed) were searched systematically to identify eligible studies, which were published since the publication of the study by Rivers in 2001 \[[@CR7]\]. The search process of PubMed was showed in Additional file [1](#MOESM1){ref-type="media"}. Additionally, the bibliography of each relevant study was also examined to limit the potential publication bias. The last update search on 5 April 2015 and there was no language restriction.

Study selection and data extraction {#Sec4}
-----------------------------------

**Inclusion criteria (P**atient, **I**ntervention, **C**omparison, **O**utcome, **S**tudy design**)**

Patients {#Sec5}
--------

Patients with severe sepsis or septic shock were included. And the diagnosis of severe sepsis and septic shock was made according to appropriate guidelines \[[@CR34], [@CR35]\].

Interventions {#Sec6}
-------------

### Standard EGDT {#Sec7}

The standard EGDT was defined in the SSC guideline including the central venous pressure (CVP) should achieve 8 to 12 mmHg, mean arterial pressure (MAP) should achieve 65 to 90 mmHg, urine output should achieve 0.5 ml/kg/h or more, and central venous oxygen saturation (ScvO~2~) should achieve 70 % or above within the first 6 h of interventions \[[@CR8]\].

Comparison {#Sec8}
----------

### Usual care {#Sec9}

The usual care was defined as conventional treatments which were at the discretion of the clinicians.

Outcomes {#Sec10}
--------

The primary endpoint was all-cause mortality. If several mortality rates were reported in one study, we preferred to use the primary one. The secondary endpoints included: the length of stay in emergency department (ED), intensive care unit (ICU) and hospital; mechanical ventilation rate, renal replacement therapy rate and ICU admission rate; the intravenous fluids volume, vasopressor use rate, dobutamine use rate, blood transfusion rate in the first 6 h, between 6 and 72 h and between 0 and 72 h; the incidence of adverse events.

Study design {#Sec11}
------------

### Randomized controlled trials (RCTs) {#Sec12}

The complete processes of study selection and data extraction were conducted by two investigators independently. The study selection was performed in three phases. Firstly, two investigators independently screened the titles and abstracts of all search results, then removed apparently irrelevant studies, and imported those potentially eligible studies into the Endnote; Secondly, the duplicated studies were excluded; Thirdly, the remaining articles were read in full text. Meanwhile, the following data were extracted from each eligible study using a pre-defined data extraction sheet: the first author, year of publication, characteristics of patients in the intervention and control group, characteristics of resuscitation strategies in the intervention and control group, mortality rate at different follow-up time, other secondary outcome endpoints and items for quality evaluation. Any discrepancy was resolved by discussion with a third investigator.

Quality assessment {#Sec13}
------------------

The methodological qualities of all included studies were assessed by two investigators independently using the Cochrane risk of bias tool. All eligible studies were judged to be "high", "unclear", or "low" risk of bias based on the following domains: random sequence generation; allocation concealment; blinding of patients and personnel; incomplete outcome data; selective outcome reporting; other bias. Any one or more of the above domains were considered to be at high risk of bias, and then the study would be judged to be at high risk of bias \[[@CR36], [@CR37]\]. Only when all key domains were considered to be at low risk of bias, would be the study judged to be at low risk of bias. In other cases, the risks of bias were judged to be unclear \[[@CR36], [@CR37]\].

Data analysis {#Sec14}
-------------

The primary endpoint was all-cause mortality. We prefer to use all-cause mortality which was the primary endpoint in individual study. The metrics of odds ratio (OR) and weighted mean difference (WMD) were used to analysis dichotomous variables and continuous variables separately. Heterogeneity between studies was assessed qualitatively using the Mantel-Haenszel chi-square test and quantitatively using the I ^2^ statistics \[[@CR38], [@CR39]\]. When P ≤ 0.1 or I^2^ ≥ 50 %, there was significant heterogeneity between included studies, and random-effect model was used, otherwise the fixed-effect model was used \[[@CR40]\]. The publication bias was evaluated using funnel plot and Egger's test \[[@CR41]\].

Post hoc subgroup analysis {#Sec15}
--------------------------

ProCESS, ARISE and ProMISe are published recently and are consistent in study design \[[@CR6], [@CR30], [@CR31]\]. Thus, we pooled the primary and secondary endpoints repeatedly based on the above three studies, when required data were available.

In actually, the results of a meta-analysis are the accumulation of results of all eligible studies. Therefore, it is vulnerable to random errors deriving from sparse data and repetitive testing of accumulated data \[[@CR42]\]. In addition, enough sample size is necessary for a meta-analysis. Trial sequential analysis (TSA) is the best available approach to calculate the optimal required information size (meta-analysis sample size) for a meta-analysis \[[@CR43]\]. TSA was performed in our meta-analysis based on the average baseline mortality rate of control group, a relative risk reduction of 20 \[[@CR6], [@CR30], [@CR31]\], 80 of power, and a type I error of 5 %. The random errors adjusted monitoring boundaries were constructed to determine whether new clinical trials were still required to confirm the present conclusion \[[@CR43]--[@CR44]\]. Statistical analyses were performed on Revman 5.2.5, STATA (SERIAL NO. 40120519635) and TSA V.0.9 β (<http://www.ctu.dk/tsa/>).

Results {#Sec16}
=======

After excluding the reduplicative, non-relevant studies and other studies that did not meet our inclusion criteria, 6 studies comparing standard EGDT with usual care in patients with severe sepsis and septic shock were eligible \[[@CR6], [@CR7], [@CR30], [@CR31], [@CR45], [@CR46]\]. The flow chart of literature selection and corresponding exclusion reasons are summarized in Fig. [1](#Fig1){ref-type="fig"}. Among the included studies, 2 studies from China \[[@CR45], [@CR46]\], 2 studies from the USA \[[@CR6], [@CR7]\], 1 study from Australia \[[@CR30]\], and 1 study from the UK \[[@CR31]\]. A total of 2160 patients in the EGDT group and 2176 patients in the control group were included. Two studies included patients with severe sepsis and septic shock who stayed in the intensive care units (ICU) \[[@CR45], [@CR46]\], and the remaining four studies included patients with severe sepsis and septic shock who presenting to the emergency department (ED) \[[@CR6], [@CR7], [@CR30], [@CR31]\]. All studies started EGDT for resuscitation within 6 h. The detailed characteristics of individual eligible study are listed in Table [1](#Tab1){ref-type="table"}.Fig. 1Flow chart for study selectionTable 1Characteristics of included studies in the meta-analysisStudy/YearCountrySettingNo. of patientsResuscitation goalsOutcome^a^InterventionControlInterventionControlRivers \[[@CR7]\]/2001AmericaEemergency department130133SvO~2~ ≥ 70 % CVP 8--12 mmHg MAP 65--90 mmHg Urine volume ≥0.5 ml/kg/hCVP 8--12 mmHg\
MAP 65--90 mmHg\
Urine volume ≥0.5 ml/kg/hHospital mortalityWang \[[@CR45]\]/2006ChinaICU1617SvO~2~ ≥ 70 % CVP 8--12 mmHg MAP ≥65 mmHg Urine volume ≥0.5 ml/kg/hMAP ≥65 mmHg Urine volume ≥0.5 ml/kg/h14 days mortalityYan \[[@CR46]\]/2010ChinaICU157146ScvO~2~ ≥ 70 % CVP 8--12 mmHg SBP \>90 mmHg MAP ≥65 mmHg Urine volume ≥0.5 ml/kg/hCVP 8--12 mmHg\
SBP \>90 mmHg\
MAP ≥65 mmHg Urine volume ≥0.5 ml/kg/hICU mortalityProCESS \[[@CR6]\]/2014AmericaEemergency department439456ScvO~2~ ≥ 70 % CVP 8--12 mmHg MAP 65--90 mmHg Urine volume ≥0.5 ml/kg/hUsual careHospital mortalityARISE \[[@CR30]\]/2014Australia/New ZealandEemergency department793798SpO~2~ ≥ 93 % ScvO~2~ ≥ 70 % CVP (Self-ventilation) \>8 CVP (Non-invasive/invasive MV) \>12 mmHg\
MAP 65--90 mmHg Urine volume ≥0.6 ml/kg/h Haematocrit ≥30 %Usual care90 days mortalityProMISe \[[@CR31]\]/2015UKEemergency department625626ScvO~2~ ≥ 70 % CVP 8--12 mmHg MAP 65--90 mmHg Urine volume ≥0.5 ml/kg/hUsual care90 days mortality*CVP* central venous pressure, *MAP* mean arterial pressure, *ScvO* ~*2*~ central venous oxygen saturation^a^primary outcome

Methodological quality {#Sec17}
----------------------

Four included studies were rated as low risk of bias \[[@CR6], [@CR7], [@CR30], [@CR31]\] and the remaining studies were rated as unclear risk of bias due to the insufficiency of definitive describe of randomization and allocation concealment \[[@CR45], [@CR46]\]. The methodological qualities of all included studies are presented in Fig. [2](#Fig2){ref-type="fig"}.Fig. 2Risk of bias summary

Primary outcome: mortality {#Sec18}
--------------------------

The mortality of patients in the standard EGDT group was 24.2 (522/2160) and the mortality rate of patients in the usual care group was 25.7 % (559/2176) \[[@CR6], [@CR7], [@CR30], [@CR31], [@CR45], [@CR46]\]. The pooled results indicated that, there was no significant difference in overall mortality rate between study group and control group, and the pooled odds ratio was 0.83 (95 % confident interval, CI, 0.64--1.08) in the random-effect model, and 0.91 (95 % CI, 0.79--1.05) in the fixed effect model. However, there was significant heterogeneity between studies (*p* = 0.02, I^2^ = 64 %) (Fig. [3](#Fig3){ref-type="fig"}). What should be noted here was that the average mortality rate of the ProCESS, ARISE, and ProMISe studies \[[@CR6], [@CR30], [@CR31]\] was significantly lower than other old studies (22.2 % vs 48 %) \[[@CR7], [@CR45], [@CR46]\]. In a post hoc subgroup analysis of these three RCTs \[[@CR6], [@CR30], [@CR31]\], the efficacy of EGDT compared with usual care was 1.03 (95 % CI, 0.89--1.21) in the fixed effect model, with no heterogeneity (*p* = 0.78, *I*^*2*^ = 0 %) (Fig. [3](#Fig3){ref-type="fig"}). On the contrary, the pooled OR of the remaining old studies was 0.52 (95 % CI, 0.37--0.73) in the fixed effect model, with no heterogeneity (*p* = 1.0, *I*^*2*^ = 0 %) (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Forest plot showing the effects of early goal-direced therapy on all-cause mortality in patients with severe sepsis and septic shock

TSA was performed for all 6 studies and 3 homogeneous RCTs (ProCESS, ARISE, and ProMISe). In the former analysis, TSA showed that the diversity adjusted information size was 7536 and the cumulative Z-curve both did not surpassed the conventional boundary and trial sequential monitoring boundary for benefit or harm, as well as did not achieve the optimal information size which indicated the current results were not robust, and further clinical trials were required. However, the above results of TSA were gained based on 6 studies with significant heterogeneity (Fig. [4](#Fig4){ref-type="fig"}). The TSA of 3 homogeneous RCTs showed the diversity adjusted information size was 2457 and the cumulative Z-curve did not surpassed the conventional boundary and the trial sequential monitoring boundary for benefit or harm, but achieved the optimal information size which indicated the current results were robust, namely there was no significant difference in mortality between the two groups (Fig. [5](#Fig5){ref-type="fig"}).Fig. 4Trial sequential analysis of all-cause mortality in patients with severe sepsis and septic shock. Trial sequential analyses assessing the effect of early goal-direced therapy on all-cause mortality in 6 studies. The diversity-adjusted required information size was based on a relative risk reduction of 20; an alpha of 5; a beta of 2 and an event proportion of 25.7 % in the control arm. The blue cumulative z curve was constructed using a random effects modelFig. 5Trial sequential analysis of all-cause mortality in patients with severe sepsis and septic shock of ProCESS, ARISE and ProMISe. Trial sequential analyses assessing the effect of early goal-direced therapy on all-cause mortality in 3 multicenter harmonious studies. The diversity-adjusted required information size was based on a relative risk reduction of 20; an alpha of 5; a beta of 2 and an event proportion of 22.2 %in the control arm. The blue cumulative z curve was constructed using a random effects model

Additionally, as mortality rates at different follow-up time-points were reported in each included study, we pooled these results separately and found there was also no significant difference in ICU-mortality (OR 0.68 95 CI, 0.44--1.06), hospital mortality (OR 0.85 95 CI, 0.61--1.17), 28-day mortality (OR 0.72, 95 CI, 0.51--1.04), 60 mortality (OR 0.82, 95 CI, 0.41--1.64) and 90-day mortality (OR 0.98, 95 % CI, 0.84--1.14) (see Additional file [2](#MOESM2){ref-type="media"}) between two groups.

Secondary endpoint-1: length of stay in the ED, ICU, and hospital {#Sec19}
-----------------------------------------------------------------

The ED-LOS, ICU-LOS and hospital-LOS were reported as median and interquartile range in some studies, which might limit the quantitatively pool of results (Table [2](#Tab2){ref-type="table"}). ED-LOS was reported in the study by Yan \[[@CR46]\] and the ARISE and ProMISe studies \[[@CR30], [@CR31]\]. In the ARISE study, the authors reported that EGDT was associated with shorter ED time, however, this effect of EGDT was not found in Yan's study and the ProMISe study \[[@CR30]\]. ICU-LOS was reported in the ProCESS, ARISE and ProMISe studies \[[@CR6], [@CR30], [@CR31]\]. And the pooled results showed that there was no effect of EGDT on ICU-LOS (MD 0.05, 95%CI −0.43 - 0.53) with no significant heterogeneity (I^2^ = 17 %, *p* = 0.3) (see Additional file [3](#MOESM3){ref-type="media"}). Hospital-LOS was reported in the study by Rivers and the ProCESS, ARISE and ProMISe studies \[[@CR6], [@CR7], [@CR30], [@CR31]\]. The pooled results showed there was also no effect of EGDT on hospital-LOS (MD −0.07, 95%CI −1.12 - 0.97) with no heterogeneity (I^2^ = 0 %, *p* = 0.73). (see Additional file [4](#MOESM4){ref-type="media"}). After removing the study by Rivers \[[@CR7]\], the pooled results was −0.11 (95%CI −1.21 - 1.00), with no heterogeneity (I^2^ = 0 %, *p* = 0.53).Table 2Characteristics of included studies on ED-LOS/ICU-LOS/Hospital-LOSED-LOSICU-LOSHospital-LOSAuthorEGDTUsual carePEGDTUsual carePEGDTUsual carePYan \[[@CR45]\]19.9 ± 2.2^a^20.6 ± 1.9^a^0.82NANANANANANARivers \[[@CR7]\]NANANANANANA13.2 ± 13.8^a^13 ± 13.7^a^0.54ProCESS \[[@CR6]\]NANANA5.1 ± 6.3^a^4.7 ± 5.8^a^0.6311.1 ± 10^a^11.3 ± 10.9^a^0.25ARISE \[[@CR30]\]1.4 (0.5--2.7)^b^2.0 (1.0--3.8)^b^0.0012.8 (1.4--5.1)^b^2.8 (1.5--5.7)^b^0.818.2 (4.9--16.7)^b^8.5 (4.9--16.5)^b^0.89ProMISe \[[@CR31]\]1.5 (0.4--3.1) ^b^1.3 (0.4--2.9)^b^0.342.6 (1.0--5.8)^b^2.2 (0.0--5.3)^b^0.0059 (4--21)^b^9 (4--18) ^b^0.46*LOS* length of stay, *ED* emergency department, *ICU* intensive care unit, *NA* no available, *P* P value^a^mean ± standard deviation; ^b^median(interquartile range)

Secondary endpoint-2: mechanical ventilation rate, renal replacement therapy rate and ICU admission {#Sec20}
---------------------------------------------------------------------------------------------------

Four studies \[[@CR6], [@CR7], [@CR30], [@CR31]\] reported data on mechanical ventilation rate, and the pooled results showed that there was no difference in mechanical ventilation rate between the two groups (OR 1.00, 95%CI 0.87 - 1.14) with moderate heterogeneity (I^2^ = 63 %, *p* = 0.04) (Table [3](#Tab3){ref-type="table"}, Additional file [5](#MOESM5){ref-type="media"}). After removing the study by Rivers \[[@CR7]\], the pooled OR was 1.04 (95%CI 0.91--1.20), with no significant heterogeneity (I^2^ = 37 %, *p* = 0.2).Table 3Characteristics of included studies on mechanical ventilation/renal replacement therapy/ICU admissionMechanical ventilationRenal replacement therapyICU admissionAuthorEGDTUsual carePEGDTUsual carePEGDTUsual carePRivers \[[@CR7]\]65/13084/1330.02NANANANANANAProCESS \[[@CR6]\]165/434146/451NA12/38211/397NA401/439393/4560.01ARISE \[[@CR30]\]238/793251/7980.52106/793108/7980.94725/793661/798NAProMISe \[[@CR31]\]179/620175/6150.988/62081/6140.62551/625467/626NA*ICU* intensive care unit, *NA* no available, *P* P value

Three studies \[[@CR6], [@CR30], [@CR31]\] reported data on renal replacement therapy rate, and the pooled results showed that there was no difference in renal replacement therapy rate between the two groups (OR 1.04, 95%CI 0.84, 1.28) with no heterogeneity (I^2^ = 0 %, *p* = 0.88) (see Additional file [6](#MOESM6){ref-type="media"}).

Additionally, EGDT was associated with more ICU admissions, and the pooled OR was 2.21 (95%CI 1.83 - 2.68), with no significant heterogeneity (*P* = 0.32; I^2^ = 13 %) (see Additional file [7](#MOESM7){ref-type="media"}).

Secondary endpoint-3: intravenous fluids volume (ml), vasopressor use rate, dobutamine use rate and blood transfusion rate from 0 to 72 h {#Sec21}
-----------------------------------------------------------------------------------------------------------------------------------------

The intravenous fluids volume was reported in five studies \[[@CR6], [@CR7], [@CR30], [@CR31], [@CR45]\] (Table [4](#Tab4){ref-type="table"}). During the 6-h intervention period, patients in the EGDT group received a larger mean volume of intravenous fluids than did those in the control group (Table [3](#Tab3){ref-type="table"}). Between 6 and 72 h, the pooled results of the ProCESS, ARISE and ProMISe studies \[[@CR6], [@CR30], [@CR31]\] showed that there was no significant difference in intravenous fluids volume between the two groups. Between 0 and 72 h, it was seemed that patients in the EGDT group received more intravenous fluids than those in the usual care group. However, the pooled results of the ProCESS and ProMISe studies \[[@CR6], [@CR31]\] showed that there was no statistical significance between the two groups (see Additional file [8](#MOESM8){ref-type="media"}).Table 4Resuscitation and processes of care from baseline to 72 h0--6 h6--72 h0--72 hAuthorEGDTUsual carePEGDTUsual carePEGDTUsual care*P*Wang \[[@CR45]\]Intravenous fluids (ml)4895 ± 210^a^2340 ± 95^a^0.01NANANANANANARivers \[[@CR7]\]Intravenous fluids (ml)4981 ± 2984^a^3499 ± 2438^a^0.0018625 ± 5162^a^10602 ± 6216^a^0.0113443 ± 6390^a^13358 ± 7729^a^0.73Vasopressor use32/11736/1190.6234/11751/1190.0343/11761/1190.02Dobutamine use16/1171/1190.00117/11710/1190.1418/11711/1190.15Blood transfusion75/11722/1190.00113/11739/1190.00180/11753/1190.001ProCESS \[[@CR6]\]Intravenous fluids (ml)2805 ± 1957^a^2279 ± 1881^a^0.00014458 ± 3878^a^4354 ± 3882^a^0.087253 ± 4605^a^6633 ± 4560^a^0.0001Vasopressor use241/439201/4560.003209/439197/4560.38265/439245/4560.05Dobutamine use35/4394/4560.000119/43910/4560.0841/43913/4560.0001Blood transfusion63/43934/4560.00187/43982/4560.54120/439102/4560.22ARISE \[[@CR30]\]Intravenous fluids (ml)1964 ± 1415^a^1713 ± 1401^a^0.0014274 ± 3071^a^4382 ± 3136^a^0.51NANANAVasopressor use528/793461/7980.001460/782401/7780.004NANANADobutamine use122/79321/7980.00174/78239/7880.001NANANABlood transfusion108/79356/7980.00186/78292/7780.61NANANAProMISe \[[@CR31]\]Intravenous fluids (ml)2226 ± 1443^a^2022 ± 1271NA4215 ± 3068^a^4366 ± 3114NA5946 ± 3740^a^5844 ± 3651^a^NAVasopressor use332/623291/625NA349/603317/603NA377/623344/625NADobut mine use113/62324/625NA107/60339/603NA139/62344/625NABlood transfusion55/62324/625NA76/60351/603NA107/62365/625NA*NA* no available, *P* P value^a^mean ± standard deviation

The results of vasopressor use rates were showed in Table [4](#Tab4){ref-type="table"}. The pooled results showed that more patients in the EGDT group received vasopressor in the first 6 h (OR 1.38, 95%CI 1.19--1.60), with no significant heterogeneity (I^2^ = 20 %, *p* = 0.29); From 6 to 72 h and 0 to 72 h, the pooled results showed that there was no significant difference in vasopressor use rate between the two groups, however, with significant heterogeneity (I^2^ = 68 and I^2^ = 78 %, separately). After removing the study by Rivers \[[@CR7]\], the pooled results showed that EGDT was associated with a higher vasopressor use rate (0--6 h: OR 1.42, 95%CI 1.25--1.62; 6--72 h: OR 1.27, 95 % 1.12--1.45; 0--72 h: OR 1.28 95%CI 1.08--1.52), with no heterogeneity (I^2^ = 0 %, *p* = 0.62; I^2^ = 0 %, *p* = 0.76; I^2^ = 0 %, *p* = 0.79, separately) (see Additional file [9](#MOESM9){ref-type="media"}).

The results of dobutamine usage rate were also showed in Table [4](#Tab4){ref-type="table"}. The pooled results showed that EGDT was associated with a higher dobutamine usage rate (0--6 h: OR 6.68, 95%CI 4.91 - 9.10; 6--72 h: OR 2.41 95%CI 1.88--3.09; 0--72 h: OR 3.40 95%CI 2.54--4.54), with no significant heterogeneity (I^2^ = 0 %, *p* = 0.55; I^2^ = 3 %, *p* = 0.38; I^2^ = 30 %, *p* = 0.24, separately). After removing the study by Rivers \[[@CR7]\], the pooled results did not change a lot (0--6 h: OR 6.43, 95%CI 4.70 - 8.80; 6--72 h: OR 2.47 95%CI 1.91 - 3.21; 0--72 h: OR 3.72 95%CI 2.72 - 5.09), with no significant heterogeneity (I^2^ = 0 %, *p* = 0.59; I^2^ = 26 %, *p* = 0.26; I^2^ = 0 %, *p* = 0.84, separately) (see Additional file [10](#MOESM10){ref-type="media"}).

Table [4](#Tab4){ref-type="table"} showed the results of transfusion rate. The pooled results showed that patients in the EGDT group received more blood transfusion than those in the control group in the first 6 h and between 0 and 72 h (OR 2.91, 95%CI 1.72 - 4.91; OR 1.75, 95%CI 1.21--2.54, separately), with significant heterogeneity (I^2^ = 81 %, *p* = 0.001; I^2^ = 65 %, *p* = 0.06). However, the above effect of EGDT was not found between 6 and 72 h (OR 0.87, 95%CI 0.51--1.46) with significant heterogeneity (I^2^ = 86 %, *p* = 0.0001). After removing the study by Rivers \[[@CR7]\], the pooled results did not change a lot (0--6 h: OR 2.16, 95%CI 1.71 - 2.73; 6--72 h: OR 1.16 95%CI 0.86 - 1.55; 0--72 h: OR 1.52 95%CI 1.12 - 2.06), with no significant heterogeneity (I^2^ = 0 %, *p* = 0.87; I^2^ = 56 %, *p* = 0.11; I^2^ = 47 %, *p* = 0.17, separately) (see Additional file [11](#MOESM11){ref-type="media"}).

Secondary endpoint-4: adverse events {#Sec22}
------------------------------------

The incidences of adverse events were reported in 3 studies \[[@CR6], [@CR30], [@CR31]\]. The pooled results showed that there were no effects of EGDT on the incidence of adverse events (OR 1.06, 95%CI 0.80 - 1.39) with moderate heterogeneity (I^2^ = 62 %, *p* = 0.07) (see Additional file [12](#MOESM12){ref-type="media"}).

Discussion {#Sec23}
==========

Six studies were identified from 2001 to 2015 enrolling a total of 4336 patients \[[@CR6], [@CR7], [@CR30], [@CR31], [@CR45], [@CR46]\]. The present meta-analysis showed that there was no difference in mortality rate of patients between the EGDT group and the usual care group. Furthermore, the results of TSA indicated that the present conclusion was robust, and no further studies were required.

Although our results showed that the application of EGDT could not reduce the mortality rate of patients with severe sepsis and septic shock, one of the most plausible explanations for the decline in mortality trends in recent years was the practice of EGDT \[[@CR47], [@CR48]\]. The following reasons may explain these inconsistencies. Due to the appealing results of the study by Rivers, EGDT gets the recommendation of the SSC guideline, and has been regarded as the standard of care in patients with severe sepsis and septic shock in many hospitals in developed areas \[[@CR7]\]. As in the ARISE study \[[@CR30]\], There was no significant difference in the mean intravenous fluid volume that had been infused prior to randomization, 61.9 % of patients in the usual-care group received central venous catheter insertion and the time of initial use of intravenous antimicrobial was similar between the two groups. Similar situation was also present in the ProCESS study \[[@CR6]\] and ProMISe study \[[@CR31]\]. That is, the essence of EGDT (early identification and diagnosis of sepsis, early fluid resuscitation and early infection control) has been penetrated into the standard of care in patients with severe sepsis and septic shock, that is why the mortality rates of patients in the ProCESS, ARISE and ProMISe \[[@CR6], [@CR30], [@CR31]\] studies were significantly lower than those in the study by Rivers \[[@CR7]\]. Here, it should be noted that the newest 3 RCTs were conducted in developed areas (one in America \[[@CR6]\], one in Australia \[[@CR30]\] and one in the UK \[[@CR31]\]). In the study by Zhu \[[@CR49]\], the authors examined the compliance of the SSC resuscitation bundle in patients presenting to the emergency department with severe sepsis and septic shock in a university affiliated hospital in China. The results showed all elements of the bundle were completed in only 1.04 % of patients, and this number was significantly lower than that in the developed areas \[[@CR50]\]. Another study also pointed out that the rate of compliance with resuscitation bundle in Asia was significantly lower than that in the Europe and America \[[@CR51], [@CR52]\]. In general, factors hindering clinicians from adhering to clinical practice guidelines include knowledge, attitude and behavior. Firstly, the imperfect understanding of the definition of severe sepsis and septic shock limits the early diagnosis of these serious conditions \[[@CR49]\]. Secondly, insufficient training of sepsis resuscitation bundle further limits the practice of the EGDT \[[@CR50], [@CR52]\]. Thirdly, as the doctor-patient contradiction is aggravating gradually especially in China, more and more severe sepsis patients are hospitalized directly, instead of receiving standard resuscitation following the SSC guideline in the emergency department \[[@CR53]\]. Fourthly, the practice of EGDT is resource-intensive. Given the insufficient number of medical staffs and disproportionate emergency visits, the application of EGDT would significantly prolong the stay in the emergency department. Meanwhile, other patients could not receive timely and effective treatment \[[@CR53], [@CR54]\]. Finally, in some low and middle income nations, blood culture, central venous pressure or blood gases measurement, lactate and central or mixed venous oxygen saturation measurement could not be performed directly in emergency department even in intensive care units \[[@CR49], [@CR52]\]. Therefore, the results of the 3 newest RCTs \[[@CR6], [@CR30], [@CR31]\] do not indicate that there is no effect of EGDT on mortality rate in patients with severe sepsis and septic shock. Instead, their findings suggest the EGDT has been regarded as the standard of care in these patients particularly in developed areas. And further studies evaluating EGDT versus usual care in patients with severe sepsis and septic shock in low or moderate countries may be required.

In recent year, several meta-analysis reported that EGDT was associated with lower risk of mortality in patients with severe sepsis and septic shock \[[@CR32], [@CR55]--[@CR57]\]. However, the rates of compliance with the SSC guideline were low in these meta-analysis, indicating that the drop in mortality is partially due to other factors. Additionally, EGDT is more capable in correcting cryptogenic shock by continuous monitoring of ScvO~2~. However, its effectiveness has been a topic of much debate and many other indicators which are more cost-effective has been proposed, including lactate concentration, base deficit, and pH \[[@CR58]\]. In a recent study, the authors concluded that fluid resuscitation therapy under the guidance of lactate concentration rate was feasible and reliable in patients with severe sepsis and septic shock \[[@CR59]\]. Furthermore, it has been reported that early lactate-guided therapy was associated with lower mortality rate in patients with severe sepsis and septic shock \[[@CR60]\]. In addition, the effectiveness of CVP was also questioned in a retrospective study \[[@CR61]\]. Excessive medical treatment is associated with unfavorable outcomes \[[@CR62]\]. Therefore, the concept of "one size fits all" is not appropriate for a complex disease state like severe sepsis or septic shock, and the new concept of "individualized goal-directed hemodynamic therapy" has been proposed \[[@CR63]\].

Strengths and limitations {#Sec24}
-------------------------

To our best knowledge, the present meta-analysis was the first to systematically evaluating the standard EGDT versus usual care in patients with severe sepsis and septic shock with TSA. Three multicenter RCTs (ProCESS, ARISE and ProMISe) were included \[[@CR6], [@CR30], [@CR31]\]. Our search strategy was broad and irrespective of language. The study selection, data extraction and methodological evaluation were rigorously performed by two investigators independently. Another advantage of our meta-analysis was TSA. The last but not least was that we prospectively registered our study protocol with PROSPERO (International prospective register of systematic reviews; CRD42015017667).

However, several limitations of our meta-analysis should be mentioned. Firstly, some studies evaluating modified EGDT were not included. Secondly, the organizational structures of EDs or ICUs, demographic characteristics of sepsis patients, and the definitions of usual cares may be different in different areas. Thirdly, SOFA-score which was a secondary endpoint in our registered protocol was replaced by length of stay in emergency department, mechanical ventilation rate, renal replacement therapy rate and the incidence of adverse events in the present meta-analysis. Finally, the number of included studies was too small to perform publication bias examination; therefore our results may be influenced by the publication bias.

Conclusions {#Sec25}
===========

The current evidence does not support the significant advantage of early goal-directed therapy (EGDT) in the resuscitation of patients with severe sepsis and septic shock. Despite the conclusion of the present meta-analysis was robust in developed areas, more designed rigorously studies are required to determine the effects of EGDT on patients with severe sepsis and septic shock in low and moderate income areas.
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